Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.58 USD
+0.04 (2.60%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.58 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LXRX 1.58 +0.04(2.60%)
Will LXRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXRX
All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
LXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates
Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for
Other News for LXRX
Analysts Are Bullish on These Healthcare Stocks: Alvotech (ALVO), Cardinal Health (CAH)
Needham Keeps Their Hold Rating on Lexicon Pharmaceuticals (LXRX)
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers
Lexicon to hold investor day